CR20240344A - Inhibidores de apol1 y métodos de uso - Google Patents
Inhibidores de apol1 y métodos de usoInfo
- Publication number
- CR20240344A CR20240344A CR20240344A CR20240344A CR20240344A CR 20240344 A CR20240344 A CR 20240344A CR 20240344 A CR20240344 A CR 20240344A CR 20240344 A CR20240344 A CR 20240344A CR 20240344 A CR20240344 A CR 20240344A
- Authority
- CR
- Costa Rica
- Prior art keywords
- apol1
- inhibitors
- methods
- yz8vxxx
- yxfsleeps
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En este documento se proporcionan compuestos de fórmula (II): <img src="data:image/png;base64,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 (***)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300592P | 2022-01-18 | 2022-01-18 | |
| US202263311668P | 2022-02-18 | 2022-02-18 | |
| US202263332553P | 2022-04-19 | 2022-04-19 | |
| US202263400359P | 2022-08-23 | 2022-08-23 | |
| US202263442341P | 2022-11-03 | 2022-11-03 | |
| PCT/US2023/060787 WO2023141432A2 (en) | 2022-01-18 | 2023-01-17 | Apol1 inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240344A true CR20240344A (es) | 2024-12-09 |
Family
ID=94538390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240344A CR20240344A (es) | 2022-01-18 | 2023-01-17 | Inhibidores de apol1 y métodos de uso |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR20240344A (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4465982A4 (en) * | 2022-01-18 | 2025-11-26 | Maze Therapeutics Inc | APOL1 INHIBITORS AND METHODS OF USE |
-
2023
- 2023-01-17 CR CR20240344A patent/CR20240344A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4465982A4 (en) * | 2022-01-18 | 2025-11-26 | Maze Therapeutics Inc | APOL1 INHIBITORS AND METHODS OF USE |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20240344A (es) | Inhibidores de apol1 y métodos de uso | |
| Li et al. | Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity | |
| NO20053114L (no) | Astma og allergisk inflammasjonsmodulatorer. | |
| Lai et al. | Histones of neutrophil extracellular traps directly disrupt the permeability and integrity of the intestinal epithelial barrier | |
| Wang et al. | Pharmacological dual inhibition of tumor and tumor-induced functional limitations in a transgenic model of breast cancer | |
| EP4473968A3 (en) | Pyridazinone compounds and uses thereof | |
| KR20230129162A9 (ko) | 제1형 근긴장성 이영양증을 치료하기 위한 rna 표적화 조성물 및 방법 | |
| Parasaram et al. | Pentagalloyl glucose increases elastin deposition, decreases reactive oxygen species and matrix metalloproteinase activity in pulmonary fibroblasts under inflammatory conditions | |
| BRPI0408466A (pt) | composições farmacêuticas de inibidores de cetp e uso dos referidos inibidores | |
| MA54903A (fr) | Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 | |
| MX2021007738A (es) | Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer. | |
| AU2021413753A9 (en) | Compositions and methods for delivery of rna | |
| ATE498022T1 (de) | Universelle vervielfältigung von fragmentierter rns | |
| WO2022212231A3 (en) | Huntingtin (htt) irna agent compositions and methods of use thereof | |
| MX2024005658A (es) | Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos. | |
| Kang et al. | PRMT6 mediates CSE induced inflammation and apoptosis | |
| Chen et al. | ERK1 loss accelerates the progression of osteoarthritis in aged mice via NRF2/BACH1 signaling | |
| Wang et al. | VPA enhances pulp regeneration by regulating LPS-induced human dental pulp stem cells odontogenic differentiation | |
| MX2025015719A (es) | Composiciones y métodos para usar conjugados de anticuerpo-oligonucleótido de direccionamiento a pln | |
| MA65143A1 (fr) | Compositions d'inhibiteur de transporteur dépendant du sodium apical | |
| JOP20250021A1 (ar) | مستحضر سائل فموي صيدلي مستقر من عامل مضاد للتشنج | |
| JPWO2013162054A1 (ja) | クロマチン構造を制御する組成物 | |
| Wongsuwanlert et al. | Effect of mouthwash containing poly L-Lysine and glycerol monolaurate on oral Helicobacter pylori relating to biofilm eradication, anti-adhesion, and pro-inflammatory cytokine suppression | |
| CA3263050A1 (en) | Compositions for targeted lysosomal degradation and their methods of use | |
| Ren et al. | Exploring the efficacy of (R)-PFI-2 hydrochloride in mitigating noise-induced hearing loss by targeting NLRP3 inflammasome and NF-κB pathway to reduce inner ear inflammation |